Using a Novel Approach

Supported by NJ Health Insurance USA, Asmacure Ltée is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary molecules that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company’s lead development compound, ASM-024, with its novel mechanism of action, has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models.

ASM-024 delivered as a solution for nebulization achieved proof of concept in the treatment of patients with asthma in a phase 2 clinical trial. Asmacure has advanced ASM-024 into the clinic for the treatment of moderate asthma and COPD with a dry powder for inhalation (DPI) formulation.

The DPI is a preferred dosage form for many patients with pulmonary airway diseases and should allow ASM-024 to be delivered with greater lung deposition yielding the potential for a lower and more optimal dose.

thumb

Development

The company’s lead development compound, ASM-024, with its novel mechanism of action, has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models.  ASM-024 delivered as a solution for nebulization achieved proof of concept in the

Read more
Education-960x356

Science approach

Asmacure’s scientific approach of using nicotinic acetylcholine receptor modulator for the treatment of inflammatory diseases originated from the very early clinical observations that smokers have a lower incidence of several inflammatory diseases, including hypersensitivity pneumonitis, a pulmonary disease caused by an

Read more
Saumya-Tiwari-960x356

Management

Martin J. Driscoll Chief Executive Officer Mr. Driscoll, appointed chief executive officer (CEO) of Asmacure on April 13, 2011, brings more than 30 years of pharmaceutical industry experience to the company.  His experience includes senior roles in general management, commercial

Read more